Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25244282 | 1.00 | MAPK1 (0.33) | MAPK1MEN1KMT2ATRPV4 | |
| SCHEMBL1164960 | 0.80 | MAPK1 (0.41) | MAPK1MEN1KMT2A | |
| SCHEMBL935034 | 0.80 | MEN1 (0.39) | MAPK1MEN1KMT2A | |
| SCHEMBL25315941 | 0.80 | MAPK1 (0.41) | MAPK1MEN1KMT2A | |
| SCHEMBL984359 | 0.80 | MAPK1 (0.41) | MAPK1MEN1KMT2A | |
| SCHEMBL24899993 | 0.78 | VNN1 (0.33) | — | |
| SCHEMBL22472913 | 0.77 | GRM5 (0.34) | MAPK1MEN1KMT2ATRPV4 | |
| SCHEMBL17101416 | 0.77 | MAPK1 (0.54) | MAPK1MEN1KMT2A | |
| SCHEMBL1574073 | 0.75 | PTPN11 (0.30) | — | |
| SCHEMBL1574072 | 0.75 | PTPN11 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617783-B2 | Heterocyclic GLP-1R agonists | BIOMEA FUSION, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-11981686-B2 | Urea compound having substituent | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-14 | — | — | US | disclosed |
| EP-3810614-B1 | BRIDGED COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LTD (GB) | 2024-03-27 | — | — | EP | disclosed |
| US-11773090-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20230058950-A1 | UREA COMPOUND HAVING SUBSTITUENT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| EP-3915558-A1 | SUBSTITUENT-INCLUDING UREA COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2021-12-01 | — | — | EP | disclosed |
| US-11028101-B2 | 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies | CTXT PTY LTD (AU) | 2021-06-08 | — | — | US | disclosed |
| EP-3426635-B1 | 3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LTD (AU) | 2021-05-05 | — | — | EP | disclosed |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-01-07 | — | — | US | disclosed |
| US-10865194-B2 | Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2020-12-15 | — | — | US | disclosed |
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
| US-20200087320-A1 | 3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LTD (AU) | 2020-03-19 | — | — | US | disclosed |
| US-20190135778-A1 | THERAPEUTICALLY ACTIVE BICYCLIC-SULPHONAMIDES AND PHARMACEUTICAL COMPOSITIONS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2019-05-09 | — | — | US | disclosed |
| US-20190092786-A1 | 3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LTD (AU) | 2019-03-28 | — | — | US | disclosed |
| EP-3426635-A1 | 3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THIER USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | Ctxt Pty Ltd (AU) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017153519-A1 | 3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THIER USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| EP-3135668-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-03-01 | — | — | EP | disclosed |
| EP-1140085-B1 | AZABICYCLOALKANES AS CCR5 MODULATORS | PHIVCO UK LTD (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-6586430-B1 | Administering azabicyclo compounds to treat human immunodeficiency virus infections and respiratory system disorders | PFIZER INC. | 2003-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135778-A1 | THERAPEUTICALLY ACTIVE BICYCLIC-SULPHONAMIDES AND PHARMACEUTICAL COMPOSITIONS | NAAA, FAAH, FAAH2 | MAPK1 3056/4885MEN1 4526/4885KMT2A 1049/4885 |
| US-11981686-B2 | Urea compound having substituent | SIRT6, SIRT1, SIRT2 | MAPK1 373/4885MEN1 1143/4885KMT2A 289/4885 |
| US-12617783-B2 | Heterocyclic GLP-1R agonists | GLP1R, GIPR, GPR119 | MAPK1 1599/4885MEN1 1163/4885KMT2A 4414/4885 |
| US-10865194-B2 | Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions | NAAA, FAAH2, FAAH | MAPK1 2712/4885MEN1 4200/4885KMT2A 988/4885 |
| US-20200087320-A1 | 3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | HBB, HBZ, HBG2 | MAPK1 3169/4885MEN1 366/4885KMT2A 110/4885 |
| US-20230058950-A1 | UREA COMPOUND HAVING SUBSTITUENT | SIRT6, SIRT1, SIRT2 | MAPK1 373/4885MEN1 1143/4885KMT2A 289/4885 |
| US-11773090-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | MAPK1 1738/4885MEN1 279/4885KMT2A 2887/4885 |
| US-11028101-B2 | 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies | HBB, HBZ, HBG2 | MAPK1 3165/4885MEN1 362/4885KMT2A 110/4885 |
| US-20190092786-A1 | 3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | HBB, HBG2, HBZ | MAPK1 3179/4885MEN1 337/4885KMT2A 112/4885 |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | MAPK1 1738/4885MEN1 279/4885KMT2A 2887/4885 |
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | MAPK1 1738/4885MEN1 279/4885KMT2A 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.